Table 1 Immunocompromised patients’ characteristics
From: Gastrointestinal bleeding in critically ill immunocompromised patients
Characteristics | Patients N = 141 |
|---|---|
Generalities | |
Age, median [IQR] | 60 [48–69] |
Male gender, n (%) | 89 (63) |
BMI, median [IQR] | 24 [21–29] |
Immunosuppression factor | |
Hematological malignancy, n (%) | 93 (66) |
Auto-immune disease, n (%) | 17 (12) |
Solid organ transplant, n (%) | 17 (12) |
HIV, n (%) | 24 (17) |
Corticosteroids, n (%) | 72 (51) |
Chemotherapy, n (%) | 61 (43) |
Other immunosuppressive drugs, n (%) | 37 (26) |
Allograft, n (%) | 9 (6) |
Treatments at admission | |
Anticoagulants, n (%) | 36 (26) |
Antiplatelet agent, n (%) | 21 (15) |
PPI before admission, n (%) | 69 (49) |
GIB characteristics | |
Upper GIB, n (%) | 103 (73) |
Delay ICU—GIB, median [IQR], days | 0 [− 2.1 to 1.25] |
Melena, n (%) | 90 (64) |
Hematochezia, n (%) | 51 (36) |
Hematemesis, n (%) | 42 (30) |
Biology during GIB | |
Thrombopenia < 50 G/L, n (%) | 56 (40) |
Hemoglobin (nadir) (g/dl), median [IQR] | 6,6 [2, 5–7] |
PT (%), median [IQR] | 69 [57–77.5] |
ACT, median [IQR] | 1.15 [1–1.5] |
Lactatemia (mmol/l), median [IQR] | 2.1 [1.2–3.9] |
Fibrinogen (g/l), median[IQR] | 3.095 [2.062–4.825] |
Organ failure | |
Shock, n (%) | 64 (45) |
Vasopressive drugs, n (%) | 55 (39) |
Renal replacement therapy, n (%) | 44 (31) |
Mechanical ventilation, n (%) | 110 (79) |
SOFA score during GIB, median [IQR] | 6 [3–12] |
Transfusion | |
RBC units, median [IQR] | 5 [3–10] |
Platelets units, median [IQR] | 6 [0–19] |
FFP units, median [IQR] | 0 [0–2] |
Fibrinogen concentrates, n (%) | 7 (5) |
Tranexamic acid, n (%) | 5 (4) |
Etiologies | |
Ulcers, any cause, n (%) | 38 (27) |
Malignant lesion, n (%) | 36 (26) |
Variceal bleeding, n (%) | 15 (11) |
Infectious cause, n (%) | 13 (9) |
Angiodysplasia, n (%) | 8 (6) |
Noninfectious colitis, n (%) | 8 (6) |
Diverticular hemorrhage, n (%) | 4 (3) |
Graft versus host disease, n (%) | 2 (1) |
Other, n (%) | 17 (12) |
Interventional care | |
EGD, hemostatic procedure, n (%) | 59 (42) |
Colonoscopy, n (%) | 42 (30) |
CT angiography, n (%) | 34 (24) |
Arterio-embolization, n (%) | 10 (7) |
Hemostatic surgery, n (%) | 10 (7) |
AIM65 score ≥ 2, n (%) | 105 (74) |
ICU stay, median [IQR], days | 5 [2–11] |
Relapses, n (%) | 38 (27) |
ICU mortality, n (%) | 30 (21) |
Mortality at day 30, n (%) | 39 (28) |
Mortality at day 90, n (%) | 54 (38) |
Mortality due to GIB, n (%) | 18 (13) |